GlycoEra
- Biotech or pharma, therapeutic R&D
GlycoEra is developing transformative precision therapies using its best-in-class extracellular degrader platform. Our company's focus is autoimmune disease but our platform can be applied across therapeutic areas. We have recently announced our lead program is designed rapidly and deeply degrade IgG4 which is a pathogenic actor in a diverse set of autoimmune diseases. Our platform is modular and enables the development of highly selective and potent degraders to wide variety of circulating targets. We are interested in strategic partnerships to broaden the impact of our programs and platform.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}